SlideShare a Scribd company logo
1 of 100
TTP/HUS r 
Questions & Answers 
Mohammed Abdel Gawad 
Nephrology Specialist 
Kidney & Urology Center (KUC) 
Alexandria 
drgawad@gmail.com 
ESNT Outreach Program, Sohag, December 4-7, 2014
To download the lecture with full 
animations please contact me on 
drgawad@gmail.com
Questions 
What is meant by Thrombotic Microangiopathy 
(TMA)? 
What are the causes of TMA? 
What is the mechanism of TMA in TTP-HUS? 
What is the diagnostic approach of TTP-HUS & 
TMA? 
What are the treatment protocols of TTP-HUS? 
1
Questions 
What is meant by Thrombotic Microangiopathy 
(TMA)? 
What are the causes of TMA? 
What is the mechanism of TMA in TTP-HUS? 
What is the diagnostic approach of TTP-HUS & 
TMA? 
What are the treatment protocols of TTP-HUS? 
1
What is meant by Thrombotic 
Microangiopathy (TMA)? 
Intraluminal platelet thrombosis 
Thrombocytopenia 
Microangiopathic hemolytic 
anemia 
Consumption of 
platelets 
Hemolysis, Anemia, ↑LDH & 
Bilirubin 
1
Questions 
What is meant by Thrombotic Microangiopathy 
(TMA)? 
What are the causes of TMA? 
What is the mechanism of TMA in TTP-HUS? 
What is the diagnostic approach of TTP-HUS & 
TMA? 
What are the treatment protocols of TTP-HUS? 
2
Questions 
What is meant by Thrombotic Microangiopathy 
(TMA)? 
What are the causes of TMA? 
What is the mechanism of TMA in TTP-HUS? 
What is the diagnostic approach of TTP-HUS & 
TMA? 
What are the treatment protocols of TTP-HUS? 
2
What are the causes of 
?TMA 
HIV, 
TTP/HUS 
2
Questions 
What is meant by Thrombotic Microangiopathy 
(TMA)? 
What are the causes of TMA? 
What is the mechanism of TMA in TTP-HUS? 
What is the diagnostic approach of TTP-HUS & 
TMA? 
What are the treatment protocols of TTP-HUS? 
2
Questions 
What is meant by Thrombotic Microangiopathy 
(TMA)? 
What are the causes of TMA? 
What is the mechanism of TMA in TTP-HUS? 
What is the diagnostic approach of TTP-HUS & 
TMA? 
What are the treatment protocols of TTP-HUS? 
2
What is the mechanism of 
TMA in TTP-HUS? 
Intraluminal platelet thrombosis 
Thrombocytopenia 
Microangiopathic hemolytic 
anemia 
Consumption of 
platelets 
Hemolysis, Anemia, ↑LDH & 
Bilirubin 
2
What is the mechanism of 
TMA in TTP-HUS? 
Intraluminal platelet thrombosis 
Consumption of 
platelets 
Thrombocytopenia 
TTP 
Shiga toxin HUS 
Neuraminidase HUS 
Atypical HUS 
3
What is the mechanism of 
TMA in TTP-HUS? 
Intraluminal platelet thrombosis 
Consumption of 
platelets 
Thrombocytopenia 
TTP 
Shiga toxin HUS 
Neuraminidase HUS 
Atypical HUS 
3
What is vWF role in 
?body 
Flora Peyvandi et al. Blood Transfus 2011; 9 Suppl 2:s3-s8- 
. Romijn RAP et al. J Biol Chem 2001; 276: 9985-91- 
·Leo T. Kroonen et al. Orthopedics. March 2008 - Volume 31- 
3
What is vWF role in 
?body 
vWF activation = Platelets 
Aggregation & Adhesion 
Flora Peyvandi et al. Blood Transfus 2011; 9 Suppl 2:s3-s8- 
. Romijn RAP et al. J Biol Chem 2001; 276: 9985-91- 
·Leo T. Kroonen et al. Orthopedics. March 2008 - Volume 31- 
3
TTP - Classification 
- H-M Tsai. Kidney International (2006) 70, 16–23. 
-Tsai HM. Annu Rev Med 2006; 57: 419–436. 
- Allford SL et al. Br J Haematol. 2003;120:556-573. 
5
What is the mechanism of 
TMA in TTP-HUS? 
Intraluminal platelet thrombosis 
Consumption of 
platelets 
Thrombocytopenia 
TTP 
Shiga toxin HUS 
ADAMTS 13 
Neuraminidase HUS 
Atypical HUS 
6
What is the mechanism of 
TMA in TTP-HUS? 
Intraluminal platelet thrombosis 
Consumption of 
platelets 
Thrombocytopenia 
TTP 
Shiga toxin HUS 
ADAMTS 13 
Neuraminidase HUS 
Atypical HUS 
6
Shiga Toxin 
Associated HUS 
E. coli (STEC) 
S. dysenteriae 
watery or most 
often bloody 
diarrhea 
E.Coli: 
Mostly the serotype O157:H7, 
but also other serotypes, such 
as O111:H8, O103:H2, O123, 
O26, O145, and the O104:H4 
strain of the recent German 
outbreak 
Mead PS, Griffin PM. Lancet.1998;352:1207-1212. 
Ruggenenti P, Remuzzi G.Lancet. 2011;378:1057-1058. 
6
Shiga Toxin 
Associated HUS 
E. coli (STEC) 
S. dysenteriae 
watery or most 
often bloody 
diarrhea 
Mead PS, Griffin PM. Lancet.1998;352:1207-1212. 
Ruggenenti P, Remuzzi G.Lancet. 2011;378:1057-1058. 
6
Shiga Toxin 
Associated HUS 
E. coli (STEC) 
S. dysenteriae 
watery or most 
often bloody 
diarrhea 
Morigi M et al. Blood. 2001;98:1828-1835. 
Morigi M et al. J Immunol. 2011;187:172-180. 
7
Shiga Toxin 
Associated HUS 
E. coli (STEC) 
S. dysenteriae 
watery or most 
often bloody 
diarrhea 
Complement 
activation by 
alternative 
pathway: 
High plasma 
levels of 
complement 
activation 
products 
Bb and C5b-9 
were 
measured in 
children with 
STEC-HUS 
Morigi M et al. Blood. 2001;98:1828-1835. 
Morigi M et al. J Immunol. 2011;187:172-180. 
7
What is the mechanism of 
Intraluminal platelet thrombosis 
Consumption of 
platelets 
Thrombocytopenia 
TTP 
Shiga toxin HUS 
ADAMTS 13 
Neuraminidase HUS 
Atypical HUS 
Toxin binds 
endothelium 
TMA in TTP-HUS? 
8
What is the mechanism of 
Intraluminal platelet thrombosis 
Consumption of 
platelets 
Thrombocytopenia 
TTP 
Shiga toxin HUS 
ADAMTS 13 
Neuraminidase HUS 
Atypical HUS 
Toxin binds 
endothelium 
TMA in TTP-HUS? 
8
Neuraminidase 
Associated HUS 
In infants and children. Complicate pneumonia, or less 
frequently, meningitis caused by S. pneumoniae 
erythrocytes, platelets, 
glomerular cells 
Brandt J, Wong C, Mihm S, et al. Pediatrics. 2002;110:371-376. 
Thomsen-Friedenreich antigen 
8
Neuraminidase 
Associated HUS 
In infants and children. Complicate pneumonia, or less 
frequently, meningitis caused by S. pneumoniae 
erythrocytes, platelets, 
glomerular cells 
Thomsen-Friedenreich antigen 
Polyagglutination 
Brandt J, Wong C, Mihm S, et al. Pediatrics. 2002;110:371-376. 
8
Neuraminidase 
Associated HUS 
In infants and children. Complicate pneumonia, or less 
frequently, meningitis caused by S. pneumoniae 
erythrocytes, platelets, 
glomerular cells 
Thomsen-Friedenreich antigen 
Polyagglutination 
Brandt J, Wong C, Mihm S, et al. Pediatrics. 2002;110:371-376. 
8 
Coomb’s +ve
What is the mechanism of 
Intraluminal platelet thrombosis 
Consumption of 
platelets 
Thrombocytopenia 
TTP 
Shiga toxin HUS 
ADAMTS 13 
Neuraminidase HUS 
Atypical HUS 
Toxin binds 
endothelium 
TMA in TTP-HUS? 
8
What is the mechanism of 
Intraluminal platelet thrombosis 
Consumption of 
platelets 
Thrombocytopenia 
TTP 
Shiga toxin HUS 
ADAMTS 13 
Neuraminidase HUS 
Atypical HUS 
Toxin binds 
endothelium 
TMA in TTP-HUS? 
8
Atypical HUS 
Low serum C3 levels in aHUS with 
normal C4 indicate selective 
.alternative pathway activation 
Noris M, Ruggenenti P, Perna A, et al. J Am Soc Nephrol. 1999;10:281-293. 
9
Atypical HUS 
Caprioli J et al. Blood. 2006;108:1267-1279. 
Manuelian T, et al. J Clin Invest. 2003;111:1181-1190. 
9
Atypical HUS 
9
Atypical HUS 
10
Atypical HUS 
Acquired defects of CFH function are also 
seen in the form of inhibitory antibodies, 
reported in 5% to 10% of aHUS patients. 
Dragon-Durey MA, Loirat C, Cloarec S, et al. J Am Soc Nephrol. 2005;16:555-563. 
10
Atypical HUS 
10
What is the mechanism of 
Intraluminal platelet thrombosis 
Consumption of 
platelets 
Thrombocytopenia 
TTP 
Shiga toxin HUS 
ADAMTS 13 
Neuraminidase HUS 
Atypical HUS 
Toxin binds 
endothelium 
Alternative 
Complement 
TMA in TTP-HUS? 
10
What is the mechanism of 
TMA in TTP-HUS? 
Intraluminal platelet thrombosis 
Thrombocytopenia 
Microangiopathic hemolytic 
anemia 
Consumption of 
platelets 
Hemolysis, Anemia, ↑LDH & 
Bilirubin 
11
TTP – MAHA 
11
To download the lecture with full 
animations please contact me on 
drgawad@gmail.com
Questions 
What is meant by Thrombotic Microangiopathy 
(TMA)? 
What are the causes of TMA? 
What is the mechanism of TMA in TTP-HUS? 
What is the diagnostic approach of TTP-HUS & 
TMA? 
What are the treatment protocols of TTP-HUS? 
12
Questions 
What is meant by Thrombotic Microangiopathy 
(TMA)? 
What are the causes of TMA? 
What is the mechanism of TMA in TTP-HUS? 
What is the diagnostic approach of TTP-HUS & 
TMA? 
What are the treatment protocols of TTP-HUS? 
12
Marie Scully et al. British Journal 
of Haematology, 2012, 158, 323– 
335. 
HIV, 
DD of 
thrombocytopenia 
& MAHA 
Systematic Approach 
of Diagnosis 
12
Systematic Approach 
Marie Scully et al. British Journal 
of Haematology, 2012, 158, 323– 
335. 
of Diagnosis 
Step 1 – 
Exclude Drugs 
12
Systematic Approach 
Piero Ruggenenti, Comprehensive 
Clinical Nephrology. 4th edition, 
chapter 28, p353 
of Diagnosis 
Step 1 – 
Exclude Drugs 
12
Systematic Approach 
of Diagnosis 
Step 1 – Exclude 
Drugs 
Step 1 – 
Exclude Drugs 
12
Systematic Approach 
of Diagnosis 
- Marie Scully et al. British Journal of Haematology, 2012, 158, 323–335. 
- Patton JF et al. Am J Hematol. 1994;47:94-99. 
Step 2 – Autoimmune 
Hemolysis 
13
Systematic Approach 
of Diagnosis 
- Marie Scully et al. British Journal of Haematology, 2012, 158, 323–335. 
- Patton JF et al. Am J Hematol. 1994;47:94-99. 
Step 2 – Autoimmune 
Hemolysis 
13
Systematic Approach 
of Diagnosis 
- Marie Scully et al. British Journal of Haematology, 2012, 158, 323–335. 
- Patton JF et al. Am J Hematol. 1994;47:94-99. 
Step 2 – Autoimmune 
Hemolysis 
Step 
3 
13
Systematic Approach 
of Diagnosis 
Step 3 – 
Coagulation Profile 
Step 4 – Exclude other causes 
14
Systematic Approach 
of Diagnosis 
Step 4 – Exclude other causes 
DD Suggestive Criteria 
Malignant 
Hypertension 
• Patient will have severe HTN: for example, systolic BP >200 
mmHg, diastolic BP >130 mmHg. 
• It is extremely unlikely that a patient with TTP will present with 
severe HTN. 
• Microangiopathic haemolysis in patients with malignant HTN 
clears and thrombocytopenia resolves with BP management. 
Pre-eclampsia 
• New BP elevation and proteinuria after 20 weeks of gestation 
in a pregnant woman. 
• Although pregnancy is a risk factor for TTP and proteinuria 
can be present, patients with TTP do not generally have raised 
BP. 
15
Systematic Approach 
of Diagnosis 
Step 4 – Exclude other causes 
DD Suggestive Criteria 
Sepsis 
• Sepsis patients have hypotension 
• More pronounced fever 
• Raised white count with left shift. 
• Peripheral smear: vacuoles in the cytoplasm of 
neutrophils (highly specific for bacteraemia) 
• Blood cultures might be positive. 
Pregnancy Must be excluded. 
Autoimmune 
Disease 
ANA, RF, antiDNA, ACLA, lupus anticoagulant 
16
Systematic Approach 
of Diagnosis 
Step 4 – Exclude other causes 
HIV, 
17
Systematic Approach 
of Diagnosis 
Step 4 – Exclude other causes 
17
Systematic Approach 
of Diagnosis 
Step 4 – Exclude other causes 
• TTP has been reported in 
association with acute pancreatitis. 
• Sometimes a number of days 
after resolution of pancreatitis. 
• All patients were successfully 
treated with PEX and 
corticosteroids (McDonald et al, 
2009). 
An association between 
thrombocytopenia and 
thyrotoxicosis has been 
reported 
17
Systematic Approach 
of Diagnosis 
Atypical HUS TTP 
Step 5 – 
TTP vs HUS 
Shiga toxin- 
HUS 
Neuraminidase 
-HUS 
18
Systematic Approach 
of Diagnosis 
Step 5 – TTP vs HUS 
Shiga toxin- 
HUS 
- Less than 2 years old 
- Respiratory distress, 
neurologic 
involvement, 
and coma. 
Neuraminidase 
-HUS 
- Occurs primarily in children, (except 
in epidemics with any age) 
-Watery or bloody diarrhoea. 
- Stool Culture: detection of E. coli 
O157:H7 and other STEC and their 
products in stool cultures (sorbitol-containing 
MacConkey agar - SMAC) 
Mead PS, Griffin PM. Lancet. 1998;352:1207-1212. 
18
Systematic Approach 
of Diagnosis 
Step 5 – TTP vs HUS 
Shiga toxin- 
HUS 
- Less than 2 years old 
- Respiratory distress, 
neurologic 
involvement, 
and coma. 
Neuraminidase 
-HUS 
- Occurs primarily in children, (except 
in epidemics with any age) 
-Watery or bloody diarrhoea. 
- Stool Culture: detection of E. coli 
O157:H7 and other STEC and their 
products in stool cultures (sorbitol-containing 
MacConkey agar - SMAC) 
Mead PS, Griffin PM. Lancet. 1998;352:1207-1212. 
18
Systematic Approach 
of Diagnosis 
Atypical HUS TTP 
Step 5 – 
TTP vs HUS 
Shiga toxin- 
HUS 
Neuraminidase 
-HUS 
19
Systematic Approach 
of Diagnosis 
Step 5 – TTP vs HUS 
Atypical HUS TTP 
Difficult to distinguish on clinical grounds only 
Moschcowitz E. Mt Sinai J Med. 2003;70:352-355. 
19
Systematic Approach 
of Diagnosis 
Step 5 – TTP vs HUS 
Atypical HUS TTP 
Difficult to distinguish on clinical grounds only 
TTP Pentad: 
1. Microangiopathic haemolytic anaemia 
2. Thrombocytopenia with purpura 
3. Acute renal insufficiency 
4. Neurological abnormalities 
5. Fever 
is rare for all of these features (TTP pentad) to be seen. 
19 
-Vesely SK et al. Blood. 2003;102:60-68. 
-Marie Scully et al. British Journal of Haematology, 2012, 158, 323–335.
Systematic Approach 
of Diagnosis 
Step 5 – TTP vs HUS 
Atypical HUS TTP 
Difficult to distinguish on clinical grounds only 
Differential diagnosis of aHUS is made on exclusion: 
• Of infections by STEC or neuraminidase - producing 
S.pneumoniae, 
• Of ADAMTS13 deficiency, 
• Of Systemic-associated diseases 
20
Systematic Approach 
of Diagnosis 
Step 5 – TTP vs HUS 
Atypical HUS TTP 
Difficult to distinguish on clinical grounds only 
Moschcowitz E. Mt Sinai J Med. 2003;70:352-355. 
Eknoyan G, Riggs SA. Am J Nephrol. 1986;6:117-131. 20
Systematic Approach 
of Diagnosis 
Step 1: Exclusion of drugs 
Step 2: Exclusion of Autoimmune hemolysis 
Step 3: Coagulation Profile 
Step 4: Exclusion of other systemic causes 
Step 5: TTP vs HUS? 
20
Questions 
What is meant by Thrombotic Microangiopathy 
(TMA)? 
What are the causes of TMA? 
What is the mechanism of TMA in TTP-HUS? 
What is the diagnostic approach of TTP-HUS & 
TMA? 
What are the treatment protocols of TTP-HUS? 
21
Questions 
What is meant by Thrombotic Microangiopathy 
(TMA)? 
What are the causes of TMA? 
What is the mechanism of TMA in TTP-HUS? 
What is the diagnostic approach of TTP-HUS & 
TMA? 
What are the treatment protocols of TTP-HUS? 
21
Shiga Toxin 
Associated HUS 
E. coli (STEC) 
S. dysenteriae 
watery or most 
often bloody 
diarrhea 
Morigi M et al. Blood. 2001;98:1828-1835. 
Morigi M et al. J Immunol. 2011;187:172-180. 
21
Shiga Toxin Associated 
HUS Treatment 
Generally Supportive (including RRT if required) 
No role for anticoagulation 
No role for Antitimotility agents 
21
Shiga Toxin Associated 
HUS Treatment 
Generally Supportive (including RRT if required) 
No role for Antibiotics except: 
1.Patients presenting with bacteremia 
2.HUS, hemorrhagic colitis and HUS caused by Shigella 
dysentery type 1 
3.Azithromycin had some benefit on the duration of bacterial 
shedding in adult patients from the German O104:H4 
epidemic 
21
Shiga Toxin Associated 
HUS Treatment 
Generally Supportive (including RRT if required) 
Is there a role for plasma exchange? 
No prospective RCTs are available 
But comparative analyses of two large series of patients 
treated or not treated with plasma suggest that plasma 
therapy may dramatically decrease overall mortality of STEC 
O157:H7–associated HUS. 
Dundas S et al. Lancet. 1999;354:1327-1330. 
Carter AO et al. N Engl J Med. 1987;317:1496-1500. 
22
Atypical HUS 
Mutations or 
Antibodies 
Caprioli J et al. Blood. 2006;108:1267-1279. 
Manuelian T, et al. J Clin Invest. 2003;111:1181-1190. 
22
Atypical HUS Treatment 
Plasma exchange vs Plasma infusion 
Plasma Exchange is superior to Infusion: 
1.Plasma exchange allows supplying larger amounts of 
plasma than would be possible with infusion while 
avoiding fluid overload. 
2.Remission and prevention of recurrences, by 
removal of mutant CFH. 
3.Plasma exchange is used to remove anti-CFH 
antibodies, but the effect is usually transient. 
Noris M, Remuzzi G. N Engl J Med. 2009;361:1676-1687. 
Dragon-Durey MA, et al. J Am Soc Nephrol. 2005;16:555-563. 
23
Atypical HUS Treatment 
Plasma exchange 
Immunosuppressants (corticosteroids 
and azathioprine or mycophenolate mofetil) 
combined with plasma exchange allowed long-term 
dialysis-free survival in 60% to 70% of 
patients. 
Dragon-Durey MA et al. J Am Soc Nephrol. 2010;21:2180-2187. 
24
Atypical HUS Treatment 
Licht C et al. J Am Soc Nephrol. 2011;22:197A. 
Greenbaum LA et al. J Am Soc Nephrol. 2011;22:197A. 
24
HUS Treatment 
24 
STEC - HUS Atypical HUS 
• General supportive 
• No anticoagulation 
• No antimotility drugs 
• No antibiotics (except some 
situations) 
• ??? PEX 
• Plasma Therapy (PEX is 
better) + 
Immunosuppressives 
• Eculizmab
TTP - Classification 
- H-M Tsai. Kidney International (2006) 70, 16–23. 
-Tsai HM. Annu Rev Med 2006; 57: 419–436. 
- Allford SL et al. Br J Haematol. 2003;120:556-573. 
25 
ADAMTS13 activity 
< 5%, absence of 
Abs to ADAMTS13.
Acquired TTP Treatment 
First Line Therapy 
25
Acquired TTP Treatment 
First Line Therapy 
25
What is the ideal time to start PEX sessions? 
25 
Acquired TTP Treatment 
First Line Therapy
What is the ideal initial volume of exchange? 
X plasma 5·1 
volume (PV) 
exchange on the 
first 3 d 
followed by 1·0 PV 
exchange 
thereafter 
Canadian ( 
apheresis trial 
)regimen 
26 
Acquired TTP Treatment 
First Line Therapy
When to intensify PEX? 
1. Refractory TTP (Progression of clinical 
symptoms or persistent thrombocytopenia despite 
seven daily PEX procedures) 
2. New neurological insult 
3. New cardiac insult 
26 
Acquired TTP Treatment 
First Line Therapy
When to stop PEX? 
27 
Acquired TTP Treatment 
First Line Therapy
When Plasma infusion is indicated? 
Although PEX remains the treatment 
of choice, large volume plasma 
infusions are indicated if there is to 
be a delay in arranging PEX. 
27 
Acquired TTP Treatment 
First Line Therapy 
Pereira A, Mazzara R, Monteagudo J, et al. Ann Hematol. 1995;70:319-323.
First line within 4-6 hrs 
)volume exchange( 
Highly recommended 
?? although no RCT 
If platelets 
> 50 
Specially 
when 
hemolysis 
/Clinical situation 
Hemolysis 
Only if !!!! 
sever bleeding 
?? 
If platelets > 50 
?When to intensify 
?When to stop 
28 
Acquired TTP Treatment 
First Line Therapy
Acquired TTP Treatment 
Other Options 
29
Acquired TTP Treatment 
Other Options 
29 
Refractory 
??TTP 
Relapse 
??TTP
Refractory/ 
Relapsing TTP 
29 
Refractory TTP: 
Progression of clinical symptoms or persistent 
thrombocytopenia despite seven daily PEX procedures 
Relapsing TTP: 
Episode of acute TTP more than 
30 d after remission, and occurs in 20–50% of cases.
Refractory TTP 
29
Relapsing TTP 
29
30 
Acquired TTP Treatment 
Other Options
Refractory/ - 
Resistant Cases 
Initiation - 
(cardiac, 
)neurological 
Case Reports & 
small trials but 
recommended ?? 
Trials 
30 
Acquired TTP Treatment 
Other Options
TTP - First described 
Dr. Eli Moschcowitz 
Arch Intern . Med. 1925;36:89 
30
To download the lecture with full 
animations please contact me on 
drgawad@gmail.com
Gawad 
Thank You

More Related Content

What's hot

Myelodysplastic syndrome according to WHO 2016
Myelodysplastic syndrome according to WHO 2016Myelodysplastic syndrome according to WHO 2016
Myelodysplastic syndrome according to WHO 2016Madhuri Reddy
 
Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic PurpuraThrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic PurpuraShakeel Arif
 
Approach to hemolytic anemias
Approach to hemolytic anemiasApproach to hemolytic anemias
Approach to hemolytic anemiasDr M Sanjeevappa
 
Approach to Hemolytic Anemia
Approach to Hemolytic AnemiaApproach to Hemolytic Anemia
Approach to Hemolytic AnemiaAbdullah Ansari
 
Myelodysplastic Syndrome
Myelodysplastic SyndromeMyelodysplastic Syndrome
Myelodysplastic SyndromeDr. Nurul Azam
 
Membranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis sMembranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis sMohammad Manzoor
 
Approach to patients with bleeding disorders
Approach to patients with bleeding disordersApproach to patients with bleeding disorders
Approach to patients with bleeding disordersAYM NAZIM
 
Hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosisHemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosisJagjit Khosla
 
Membranoproliferative GN - Road to Diagnosis & Management - What is the evide...
Membranoproliferative GN - Road to Diagnosis & Management - What is the evide...Membranoproliferative GN - Road to Diagnosis & Management - What is the evide...
Membranoproliferative GN - Road to Diagnosis & Management - What is the evide...NephroTube - Dr.Gawad
 
Paroxysmal nocturnal hematuria
Paroxysmal nocturnal hematuriaParoxysmal nocturnal hematuria
Paroxysmal nocturnal hematuriaAseem Jain
 
Pancytopenia Approach
Pancytopenia ApproachPancytopenia Approach
Pancytopenia ApproachVishu Bhasin
 
Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal HemoglobinuriaDebra G. Carnahan
 
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. GawadHemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. GawadNephroTube - Dr.Gawad
 

What's hot (20)

Thrombotic Microangiopathy
Thrombotic MicroangiopathyThrombotic Microangiopathy
Thrombotic Microangiopathy
 
Atypical hus
Atypical hus   Atypical hus
Atypical hus
 
Myelodysplastic syndrome according to WHO 2016
Myelodysplastic syndrome according to WHO 2016Myelodysplastic syndrome according to WHO 2016
Myelodysplastic syndrome according to WHO 2016
 
Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic PurpuraThrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
 
Pancytopenia
PancytopeniaPancytopenia
Pancytopenia
 
Approach to hemolytic anemias
Approach to hemolytic anemiasApproach to hemolytic anemias
Approach to hemolytic anemias
 
Approach to Hemolytic Anemia
Approach to Hemolytic AnemiaApproach to Hemolytic Anemia
Approach to Hemolytic Anemia
 
Approach to pancytopenia
Approach to pancytopeniaApproach to pancytopenia
Approach to pancytopenia
 
Myelodysplastic Syndrome
Myelodysplastic SyndromeMyelodysplastic Syndrome
Myelodysplastic Syndrome
 
Membranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis sMembranoproliferative glomerulonephritis s
Membranoproliferative glomerulonephritis s
 
Approach to patients with bleeding disorders
Approach to patients with bleeding disordersApproach to patients with bleeding disorders
Approach to patients with bleeding disorders
 
Hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosisHemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis
 
Membranoproliferative GN - Road to Diagnosis & Management - What is the evide...
Membranoproliferative GN - Road to Diagnosis & Management - What is the evide...Membranoproliferative GN - Road to Diagnosis & Management - What is the evide...
Membranoproliferative GN - Road to Diagnosis & Management - What is the evide...
 
Pnh
PnhPnh
Pnh
 
Paroxysmal nocturnal hematuria
Paroxysmal nocturnal hematuriaParoxysmal nocturnal hematuria
Paroxysmal nocturnal hematuria
 
Sickle cell nephropathy SCN
Sickle cell nephropathy SCNSickle cell nephropathy SCN
Sickle cell nephropathy SCN
 
Pancytopenia Approach
Pancytopenia ApproachPancytopenia Approach
Pancytopenia Approach
 
Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria
 
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. GawadHemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
Hemolytic Uremic Syndrome Induced AKI (From Pathogenesis to Bedside) - Dr. Gawad
 
Bmfs
BmfsBmfs
Bmfs
 

Viewers also liked

Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. Gawad
Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. GawadChallenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. Gawad
Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. GawadNephroTube - Dr.Gawad
 
Uremic Pruritus (Basic Science → Evidence → Practice) - Dr. Gawad
Uremic Pruritus (Basic Science → Evidence → Practice) - Dr. GawadUremic Pruritus (Basic Science → Evidence → Practice) - Dr. Gawad
Uremic Pruritus (Basic Science → Evidence → Practice) - Dr. GawadNephroTube - Dr.Gawad
 
Effective Circulating Volume Control - Dr. Gawad
Effective Circulating Volume Control - Dr. GawadEffective Circulating Volume Control - Dr. Gawad
Effective Circulating Volume Control - Dr. GawadNephroTube - Dr.Gawad
 
CKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. GawadCKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. GawadNephroTube - Dr.Gawad
 
Osmoregulation (Urine Dilution & Concentration) - Dr. Gawad
Osmoregulation (Urine Dilution & Concentration) - Dr. GawadOsmoregulation (Urine Dilution & Concentration) - Dr. Gawad
Osmoregulation (Urine Dilution & Concentration) - Dr. GawadNephroTube - Dr.Gawad
 
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. GawadDrug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. GawadNephroTube - Dr.Gawad
 
Pregnancy in End Stage Renal Disease Patients - Dr. Gawad
Pregnancy in End Stage Renal Disease Patients - Dr. GawadPregnancy in End Stage Renal Disease Patients - Dr. Gawad
Pregnancy in End Stage Renal Disease Patients - Dr. GawadNephroTube - Dr.Gawad
 
ESAs Therapy: Friend or Foe? - Dr. Gawad
ESAs Therapy: Friend or Foe? - Dr. GawadESAs Therapy: Friend or Foe? - Dr. Gawad
ESAs Therapy: Friend or Foe? - Dr. GawadNephroTube - Dr.Gawad
 
Lupus Nephritis Management (The Soft Evidence) - Dr. Gawad
Lupus Nephritis Management (The Soft Evidence) - Dr. GawadLupus Nephritis Management (The Soft Evidence) - Dr. Gawad
Lupus Nephritis Management (The Soft Evidence) - Dr. GawadNephroTube - Dr.Gawad
 
Catheter Related Blood Stream Infection (CRBSI) - (Diagnosis & Management Ste...
Catheter Related Blood Stream Infection (CRBSI) - (Diagnosis & Management Ste...Catheter Related Blood Stream Infection (CRBSI) - (Diagnosis & Management Ste...
Catheter Related Blood Stream Infection (CRBSI) - (Diagnosis & Management Ste...NephroTube - Dr.Gawad
 
Anti-Phospholipase A2 Receptor Antibody - Clinical Application for Membranous...
Anti-Phospholipase A2 Receptor Antibody - Clinical Application for Membranous...Anti-Phospholipase A2 Receptor Antibody - Clinical Application for Membranous...
Anti-Phospholipase A2 Receptor Antibody - Clinical Application for Membranous...NephroTube - Dr.Gawad
 
Effect of kidney donor hepatitis C virus serostatus on renal transplant recip...
Effect of kidney donor hepatitis C virus serostatus on renal transplant recip...Effect of kidney donor hepatitis C virus serostatus on renal transplant recip...
Effect of kidney donor hepatitis C virus serostatus on renal transplant recip...NephroTube - Dr.Gawad
 
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. Gawad
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. GawadInfection Related Glomerulopathy - Introduction – Rapid Overview - Dr. Gawad
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. GawadNephroTube - Dr.Gawad
 
Diabetes Mellitus Management - علاج داء السكري (Nursing Program) - Dr. Gawad
Diabetes Mellitus Management - علاج داء السكري (Nursing Program) - Dr. GawadDiabetes Mellitus Management - علاج داء السكري (Nursing Program) - Dr. Gawad
Diabetes Mellitus Management - علاج داء السكري (Nursing Program) - Dr. GawadNephroTube - Dr.Gawad
 
How to examine AVF in 10 minutes - Dr. Gawad
How to examine AVF in 10 minutes - Dr. GawadHow to examine AVF in 10 minutes - Dr. Gawad
How to examine AVF in 10 minutes - Dr. GawadNephroTube - Dr.Gawad
 
Chronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
Chronic Kidney Disease (CKD) - At a Glance - Dr. GawadChronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
Chronic Kidney Disease (CKD) - At a Glance - Dr. GawadNephroTube - Dr.Gawad
 
Reflective Medical Practice - Dr. Gawad
Reflective Medical Practice - Dr. GawadReflective Medical Practice - Dr. Gawad
Reflective Medical Practice - Dr. GawadNephroTube - Dr.Gawad
 
Uremic Pruritus - A life annoying problem - Dr. Gawad
Uremic Pruritus - A life annoying problem - Dr. GawadUremic Pruritus - A life annoying problem - Dr. Gawad
Uremic Pruritus - A life annoying problem - Dr. GawadNephroTube - Dr.Gawad
 
Hyponatremia (Into Practice) - Dr. Gawad
Hyponatremia  (Into Practice) - Dr. GawadHyponatremia  (Into Practice) - Dr. Gawad
Hyponatremia (Into Practice) - Dr. GawadNephroTube - Dr.Gawad
 

Viewers also liked (19)

Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. Gawad
Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. GawadChallenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. Gawad
Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. Gawad
 
Uremic Pruritus (Basic Science → Evidence → Practice) - Dr. Gawad
Uremic Pruritus (Basic Science → Evidence → Practice) - Dr. GawadUremic Pruritus (Basic Science → Evidence → Practice) - Dr. Gawad
Uremic Pruritus (Basic Science → Evidence → Practice) - Dr. Gawad
 
Effective Circulating Volume Control - Dr. Gawad
Effective Circulating Volume Control - Dr. GawadEffective Circulating Volume Control - Dr. Gawad
Effective Circulating Volume Control - Dr. Gawad
 
CKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. GawadCKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. Gawad
 
Osmoregulation (Urine Dilution & Concentration) - Dr. Gawad
Osmoregulation (Urine Dilution & Concentration) - Dr. GawadOsmoregulation (Urine Dilution & Concentration) - Dr. Gawad
Osmoregulation (Urine Dilution & Concentration) - Dr. Gawad
 
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. GawadDrug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
 
Pregnancy in End Stage Renal Disease Patients - Dr. Gawad
Pregnancy in End Stage Renal Disease Patients - Dr. GawadPregnancy in End Stage Renal Disease Patients - Dr. Gawad
Pregnancy in End Stage Renal Disease Patients - Dr. Gawad
 
ESAs Therapy: Friend or Foe? - Dr. Gawad
ESAs Therapy: Friend or Foe? - Dr. GawadESAs Therapy: Friend or Foe? - Dr. Gawad
ESAs Therapy: Friend or Foe? - Dr. Gawad
 
Lupus Nephritis Management (The Soft Evidence) - Dr. Gawad
Lupus Nephritis Management (The Soft Evidence) - Dr. GawadLupus Nephritis Management (The Soft Evidence) - Dr. Gawad
Lupus Nephritis Management (The Soft Evidence) - Dr. Gawad
 
Catheter Related Blood Stream Infection (CRBSI) - (Diagnosis & Management Ste...
Catheter Related Blood Stream Infection (CRBSI) - (Diagnosis & Management Ste...Catheter Related Blood Stream Infection (CRBSI) - (Diagnosis & Management Ste...
Catheter Related Blood Stream Infection (CRBSI) - (Diagnosis & Management Ste...
 
Anti-Phospholipase A2 Receptor Antibody - Clinical Application for Membranous...
Anti-Phospholipase A2 Receptor Antibody - Clinical Application for Membranous...Anti-Phospholipase A2 Receptor Antibody - Clinical Application for Membranous...
Anti-Phospholipase A2 Receptor Antibody - Clinical Application for Membranous...
 
Effect of kidney donor hepatitis C virus serostatus on renal transplant recip...
Effect of kidney donor hepatitis C virus serostatus on renal transplant recip...Effect of kidney donor hepatitis C virus serostatus on renal transplant recip...
Effect of kidney donor hepatitis C virus serostatus on renal transplant recip...
 
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. Gawad
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. GawadInfection Related Glomerulopathy - Introduction – Rapid Overview - Dr. Gawad
Infection Related Glomerulopathy - Introduction – Rapid Overview - Dr. Gawad
 
Diabetes Mellitus Management - علاج داء السكري (Nursing Program) - Dr. Gawad
Diabetes Mellitus Management - علاج داء السكري (Nursing Program) - Dr. GawadDiabetes Mellitus Management - علاج داء السكري (Nursing Program) - Dr. Gawad
Diabetes Mellitus Management - علاج داء السكري (Nursing Program) - Dr. Gawad
 
How to examine AVF in 10 minutes - Dr. Gawad
How to examine AVF in 10 minutes - Dr. GawadHow to examine AVF in 10 minutes - Dr. Gawad
How to examine AVF in 10 minutes - Dr. Gawad
 
Chronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
Chronic Kidney Disease (CKD) - At a Glance - Dr. GawadChronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
Chronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
 
Reflective Medical Practice - Dr. Gawad
Reflective Medical Practice - Dr. GawadReflective Medical Practice - Dr. Gawad
Reflective Medical Practice - Dr. Gawad
 
Uremic Pruritus - A life annoying problem - Dr. Gawad
Uremic Pruritus - A life annoying problem - Dr. GawadUremic Pruritus - A life annoying problem - Dr. Gawad
Uremic Pruritus - A life annoying problem - Dr. Gawad
 
Hyponatremia (Into Practice) - Dr. Gawad
Hyponatremia  (Into Practice) - Dr. GawadHyponatremia  (Into Practice) - Dr. Gawad
Hyponatremia (Into Practice) - Dr. Gawad
 

Similar to Thrombotic Thrombocytopenic Purpura / Hemolytic Uremic Syndrome (Questions & Answers) - Dr. Gawad

Thrombotic Microangiopathy (TMA) in Adults and Acute Kidney Injury - Dr. Gawad
Thrombotic Microangiopathy (TMA) in Adults and Acute Kidney Injury - Dr. GawadThrombotic Microangiopathy (TMA) in Adults and Acute Kidney Injury - Dr. Gawad
Thrombotic Microangiopathy (TMA) in Adults and Acute Kidney Injury - Dr. GawadNephroTube - Dr.Gawad
 
Moleküler Geneti̇k Kongresi̇ 2009
Moleküler Geneti̇k Kongresi̇ 2009Moleküler Geneti̇k Kongresi̇ 2009
Moleküler Geneti̇k Kongresi̇ 2009sercankuarktek
 
Thrombotic microangiopathy and the kidney - Dr. Mohamed Mamdouh AbdAlBary
Thrombotic microangiopathy and the kidney -  Dr. Mohamed Mamdouh AbdAlBaryThrombotic microangiopathy and the kidney -  Dr. Mohamed Mamdouh AbdAlBary
Thrombotic microangiopathy and the kidney - Dr. Mohamed Mamdouh AbdAlBaryMNDU net
 
Brief Communication Thombotic Trombocytopenic Purpura: Allergic Reaction to P...
Brief Communication Thombotic Trombocytopenic Purpura: Allergic Reaction to P...Brief Communication Thombotic Trombocytopenic Purpura: Allergic Reaction to P...
Brief Communication Thombotic Trombocytopenic Purpura: Allergic Reaction to P...iosrphr_editor
 
Hashimoto`s thyroiditis.pptx
Hashimoto`s thyroiditis.pptxHashimoto`s thyroiditis.pptx
Hashimoto`s thyroiditis.pptxAbdallahTEMERIK
 
Dural venus sinus thrombosis
Dural venus sinus thrombosisDural venus sinus thrombosis
Dural venus sinus thrombosissyed adnan
 
Renovascular disorder final shivaom
Renovascular disorder final shivaomRenovascular disorder final shivaom
Renovascular disorder final shivaomShivaom Chaurasia
 
Acute Promyelocytic Leukaemia
Acute Promyelocytic LeukaemiaAcute Promyelocytic Leukaemia
Acute Promyelocytic LeukaemiaDr. Renesha Islam
 
Chronic lymphocytic thyroiditis (hashimoto thyroiditis, autoimmune
Chronic lymphocytic thyroiditis (hashimoto thyroiditis, autoimmuneChronic lymphocytic thyroiditis (hashimoto thyroiditis, autoimmune
Chronic lymphocytic thyroiditis (hashimoto thyroiditis, autoimmuneDr. Saad Saleh Al Ani
 
AN INTERESTING CASE OF EXTRAMEDULLARY HEMATOPOIESIS IN A PATIENT WITH NEWLY ...
AN INTERESTING CASE OF EXTRAMEDULLARY HEMATOPOIESIS IN A PATIENT WITH  NEWLY ...AN INTERESTING CASE OF EXTRAMEDULLARY HEMATOPOIESIS IN A PATIENT WITH  NEWLY ...
AN INTERESTING CASE OF EXTRAMEDULLARY HEMATOPOIESIS IN A PATIENT WITH NEWLY ...Zisimos Solomos
 
apmlseminarmine
apmlseminarmineapmlseminarmine
apmlseminarmineicdlab
 
Bleeding disorders in children
Bleeding disorders in childrenBleeding disorders in children
Bleeding disorders in childrentrishadassarma
 
Thrombocytopenia
ThrombocytopeniaThrombocytopenia
ThrombocytopeniaSachin Giri
 

Similar to Thrombotic Thrombocytopenic Purpura / Hemolytic Uremic Syndrome (Questions & Answers) - Dr. Gawad (20)

Thrombotic Microangiopathy (TMA) in Adults and Acute Kidney Injury - Dr. Gawad
Thrombotic Microangiopathy (TMA) in Adults and Acute Kidney Injury - Dr. GawadThrombotic Microangiopathy (TMA) in Adults and Acute Kidney Injury - Dr. Gawad
Thrombotic Microangiopathy (TMA) in Adults and Acute Kidney Injury - Dr. Gawad
 
TTP HUSについて
TTP HUSについてTTP HUSについて
TTP HUSについて
 
1 s2.0-s0006497120333553-main
1 s2.0-s0006497120333553-main1 s2.0-s0006497120333553-main
1 s2.0-s0006497120333553-main
 
Noon conference 6_27_2018
Noon conference 6_27_2018Noon conference 6_27_2018
Noon conference 6_27_2018
 
Moleküler Geneti̇k Kongresi̇ 2009
Moleküler Geneti̇k Kongresi̇ 2009Moleküler Geneti̇k Kongresi̇ 2009
Moleküler Geneti̇k Kongresi̇ 2009
 
Thrombotic microangiopathy and the kidney - Dr. Mohamed Mamdouh AbdAlBary
Thrombotic microangiopathy and the kidney -  Dr. Mohamed Mamdouh AbdAlBaryThrombotic microangiopathy and the kidney -  Dr. Mohamed Mamdouh AbdAlBary
Thrombotic microangiopathy and the kidney - Dr. Mohamed Mamdouh AbdAlBary
 
MAHA/TTP/DIC/HUS/aHUS
MAHA/TTP/DIC/HUS/aHUSMAHA/TTP/DIC/HUS/aHUS
MAHA/TTP/DIC/HUS/aHUS
 
Brief Communication Thombotic Trombocytopenic Purpura: Allergic Reaction to P...
Brief Communication Thombotic Trombocytopenic Purpura: Allergic Reaction to P...Brief Communication Thombotic Trombocytopenic Purpura: Allergic Reaction to P...
Brief Communication Thombotic Trombocytopenic Purpura: Allergic Reaction to P...
 
Hashimoto`s thyroiditis.pptx
Hashimoto`s thyroiditis.pptxHashimoto`s thyroiditis.pptx
Hashimoto`s thyroiditis.pptx
 
Dural venus sinus thrombosis
Dural venus sinus thrombosisDural venus sinus thrombosis
Dural venus sinus thrombosis
 
Renovascular disorder final shivaom
Renovascular disorder final shivaomRenovascular disorder final shivaom
Renovascular disorder final shivaom
 
Acute Promyelocytic Leukaemia
Acute Promyelocytic LeukaemiaAcute Promyelocytic Leukaemia
Acute Promyelocytic Leukaemia
 
Interesting cases of young stroke
Interesting cases of young strokeInteresting cases of young stroke
Interesting cases of young stroke
 
Disorders of platelets
Disorders of plateletsDisorders of platelets
Disorders of platelets
 
Chronic lymphocytic thyroiditis (hashimoto thyroiditis, autoimmune
Chronic lymphocytic thyroiditis (hashimoto thyroiditis, autoimmuneChronic lymphocytic thyroiditis (hashimoto thyroiditis, autoimmune
Chronic lymphocytic thyroiditis (hashimoto thyroiditis, autoimmune
 
AN INTERESTING CASE OF EXTRAMEDULLARY HEMATOPOIESIS IN A PATIENT WITH NEWLY ...
AN INTERESTING CASE OF EXTRAMEDULLARY HEMATOPOIESIS IN A PATIENT WITH  NEWLY ...AN INTERESTING CASE OF EXTRAMEDULLARY HEMATOPOIESIS IN A PATIENT WITH  NEWLY ...
AN INTERESTING CASE OF EXTRAMEDULLARY HEMATOPOIESIS IN A PATIENT WITH NEWLY ...
 
apmlseminarmine
apmlseminarmineapmlseminarmine
apmlseminarmine
 
Hemostasis
HemostasisHemostasis
Hemostasis
 
Bleeding disorders in children
Bleeding disorders in childrenBleeding disorders in children
Bleeding disorders in children
 
Thrombocytopenia
ThrombocytopeniaThrombocytopenia
Thrombocytopenia
 

More from NephroTube - Dr.Gawad

Vitamin D in Chronic Kidney Disease Which type, Which dose, Which patient? - ...
Vitamin D in Chronic Kidney Disease Which type, Which dose, Which patient? - ...Vitamin D in Chronic Kidney Disease Which type, Which dose, Which patient? - ...
Vitamin D in Chronic Kidney Disease Which type, Which dose, Which patient? - ...NephroTube - Dr.Gawad
 
Urinary Tract Infection (Clinical Tips) - Dr. Gawad
Urinary Tract Infection (Clinical Tips) - Dr. GawadUrinary Tract Infection (Clinical Tips) - Dr. Gawad
Urinary Tract Infection (Clinical Tips) - Dr. GawadNephroTube - Dr.Gawad
 
Obesity and the Kidney (Link and Evidence) - Dr. Gawad
Obesity and the Kidney (Link and Evidence) - Dr. GawadObesity and the Kidney (Link and Evidence) - Dr. Gawad
Obesity and the Kidney (Link and Evidence) - Dr. GawadNephroTube - Dr.Gawad
 
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. Gawad
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. GawadAsymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. Gawad
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. GawadNephroTube - Dr.Gawad
 
ANCA vasculitis (KDIGO 2021 Guidelines) - Dr. Gawad
ANCA vasculitis (KDIGO 2021 Guidelines) - Dr. GawadANCA vasculitis (KDIGO 2021 Guidelines) - Dr. Gawad
ANCA vasculitis (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
 
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. Gawad
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. GawadLupus Nephritis (KDIGO 2021 Guidelines) - Dr. Gawad
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
 
Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadMembranous Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
 
Infection-related Glomerulonephritis (KDIGO 2021 Guidelines) - Dr. Gawad
Infection-related Glomerulonephritis  (KDIGO 2021 Guidelines) - Dr. GawadInfection-related Glomerulonephritis  (KDIGO 2021 Guidelines) - Dr. Gawad
Infection-related Glomerulonephritis (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
 
Ig & complement-mediated glomerular dis with MPGN pattern (KDIGO 2021) - Dr.G...
Ig & complement-mediated glomerular dis with MPGN pattern (KDIGO 2021) - Dr.G...Ig & complement-mediated glomerular dis with MPGN pattern (KDIGO 2021) - Dr.G...
Ig & complement-mediated glomerular dis with MPGN pattern (KDIGO 2021) - Dr.G...NephroTube - Dr.Gawad
 
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadIgA Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
 
Focal Segmental Glomerulosclerosis - FSGS (KDIGO 2021 Guidelines) - Dr. Gawad
Focal Segmental Glomerulosclerosis - FSGS (KDIGO 2021 Guidelines) - Dr. GawadFocal Segmental Glomerulosclerosis - FSGS (KDIGO 2021 Guidelines) - Dr. Gawad
Focal Segmental Glomerulosclerosis - FSGS (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
 
Adult Minimal Change Disease (KDIGO 2021 Guidelines)
Adult Minimal Change Disease (KDIGO 2021 Guidelines)Adult Minimal Change Disease (KDIGO 2021 Guidelines)
Adult Minimal Change Disease (KDIGO 2021 Guidelines)NephroTube - Dr.Gawad
 
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. GawadInsights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. GawadNephroTube - Dr.Gawad
 
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadDiabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadNephroTube - Dr.Gawad
 
Electrolytes & Acid-Base Disturbance Workshop - Dr. Gawad
Electrolytes & Acid-Base Disturbance Workshop - Dr. GawadElectrolytes & Acid-Base Disturbance Workshop - Dr. Gawad
Electrolytes & Acid-Base Disturbance Workshop - Dr. GawadNephroTube - Dr.Gawad
 
Dysproteinemias Related Renal Disorders, Monoclonal Gammopathy (Paraproteinem...
Dysproteinemias Related Renal Disorders, Monoclonal Gammopathy (Paraproteinem...Dysproteinemias Related Renal Disorders, Monoclonal Gammopathy (Paraproteinem...
Dysproteinemias Related Renal Disorders, Monoclonal Gammopathy (Paraproteinem...NephroTube - Dr.Gawad
 
Hypercalcemia (Practical Approach) - Dr. Gawad
Hypercalcemia (Practical Approach) - Dr. GawadHypercalcemia (Practical Approach) - Dr. Gawad
Hypercalcemia (Practical Approach) - Dr. GawadNephroTube - Dr.Gawad
 
CKD Progression (Pharmacological Approach) - Dr. Gawad
CKD Progression (Pharmacological Approach) - Dr. GawadCKD Progression (Pharmacological Approach) - Dr. Gawad
CKD Progression (Pharmacological Approach) - Dr. GawadNephroTube - Dr.Gawad
 
Hypocalcemia (Practical Approach) - Dr. Gawad
Hypocalcemia (Practical Approach) - Dr. GawadHypocalcemia (Practical Approach) - Dr. Gawad
Hypocalcemia (Practical Approach) - Dr. GawadNephroTube - Dr.Gawad
 

More from NephroTube - Dr.Gawad (20)

Vitamin D in Chronic Kidney Disease Which type, Which dose, Which patient? - ...
Vitamin D in Chronic Kidney Disease Which type, Which dose, Which patient? - ...Vitamin D in Chronic Kidney Disease Which type, Which dose, Which patient? - ...
Vitamin D in Chronic Kidney Disease Which type, Which dose, Which patient? - ...
 
Urinary Tract Infection (Clinical Tips) - Dr. Gawad
Urinary Tract Infection (Clinical Tips) - Dr. GawadUrinary Tract Infection (Clinical Tips) - Dr. Gawad
Urinary Tract Infection (Clinical Tips) - Dr. Gawad
 
Contrast and the kidney - Dr. Gawad
Contrast and the kidney - Dr. GawadContrast and the kidney - Dr. Gawad
Contrast and the kidney - Dr. Gawad
 
Obesity and the Kidney (Link and Evidence) - Dr. Gawad
Obesity and the Kidney (Link and Evidence) - Dr. GawadObesity and the Kidney (Link and Evidence) - Dr. Gawad
Obesity and the Kidney (Link and Evidence) - Dr. Gawad
 
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. Gawad
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. GawadAsymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. Gawad
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. Gawad
 
ANCA vasculitis (KDIGO 2021 Guidelines) - Dr. Gawad
ANCA vasculitis (KDIGO 2021 Guidelines) - Dr. GawadANCA vasculitis (KDIGO 2021 Guidelines) - Dr. Gawad
ANCA vasculitis (KDIGO 2021 Guidelines) - Dr. Gawad
 
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. Gawad
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. GawadLupus Nephritis (KDIGO 2021 Guidelines) - Dr. Gawad
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. Gawad
 
Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadMembranous Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
 
Infection-related Glomerulonephritis (KDIGO 2021 Guidelines) - Dr. Gawad
Infection-related Glomerulonephritis  (KDIGO 2021 Guidelines) - Dr. GawadInfection-related Glomerulonephritis  (KDIGO 2021 Guidelines) - Dr. Gawad
Infection-related Glomerulonephritis (KDIGO 2021 Guidelines) - Dr. Gawad
 
Ig & complement-mediated glomerular dis with MPGN pattern (KDIGO 2021) - Dr.G...
Ig & complement-mediated glomerular dis with MPGN pattern (KDIGO 2021) - Dr.G...Ig & complement-mediated glomerular dis with MPGN pattern (KDIGO 2021) - Dr.G...
Ig & complement-mediated glomerular dis with MPGN pattern (KDIGO 2021) - Dr.G...
 
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadIgA Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
IgA Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
 
Focal Segmental Glomerulosclerosis - FSGS (KDIGO 2021 Guidelines) - Dr. Gawad
Focal Segmental Glomerulosclerosis - FSGS (KDIGO 2021 Guidelines) - Dr. GawadFocal Segmental Glomerulosclerosis - FSGS (KDIGO 2021 Guidelines) - Dr. Gawad
Focal Segmental Glomerulosclerosis - FSGS (KDIGO 2021 Guidelines) - Dr. Gawad
 
Adult Minimal Change Disease (KDIGO 2021 Guidelines)
Adult Minimal Change Disease (KDIGO 2021 Guidelines)Adult Minimal Change Disease (KDIGO 2021 Guidelines)
Adult Minimal Change Disease (KDIGO 2021 Guidelines)
 
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. GawadInsights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad
 
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadDiabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
 
Electrolytes & Acid-Base Disturbance Workshop - Dr. Gawad
Electrolytes & Acid-Base Disturbance Workshop - Dr. GawadElectrolytes & Acid-Base Disturbance Workshop - Dr. Gawad
Electrolytes & Acid-Base Disturbance Workshop - Dr. Gawad
 
Dysproteinemias Related Renal Disorders, Monoclonal Gammopathy (Paraproteinem...
Dysproteinemias Related Renal Disorders, Monoclonal Gammopathy (Paraproteinem...Dysproteinemias Related Renal Disorders, Monoclonal Gammopathy (Paraproteinem...
Dysproteinemias Related Renal Disorders, Monoclonal Gammopathy (Paraproteinem...
 
Hypercalcemia (Practical Approach) - Dr. Gawad
Hypercalcemia (Practical Approach) - Dr. GawadHypercalcemia (Practical Approach) - Dr. Gawad
Hypercalcemia (Practical Approach) - Dr. Gawad
 
CKD Progression (Pharmacological Approach) - Dr. Gawad
CKD Progression (Pharmacological Approach) - Dr. GawadCKD Progression (Pharmacological Approach) - Dr. Gawad
CKD Progression (Pharmacological Approach) - Dr. Gawad
 
Hypocalcemia (Practical Approach) - Dr. Gawad
Hypocalcemia (Practical Approach) - Dr. GawadHypocalcemia (Practical Approach) - Dr. Gawad
Hypocalcemia (Practical Approach) - Dr. Gawad
 

Recently uploaded

Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfDivya Kanojiya
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfDivya Kanojiya
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxEx WHO/USAID
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSapna Thakur
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingSakthi Kathiravan
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)MohamadAlhes
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 

Recently uploaded (20)

Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdf
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdf
 
JANGAMA VISHA .pptx-
JANGAMA VISHA .pptx-JANGAMA VISHA .pptx-
JANGAMA VISHA .pptx-
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptx
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursing
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 

Thrombotic Thrombocytopenic Purpura / Hemolytic Uremic Syndrome (Questions & Answers) - Dr. Gawad

  • 1. TTP/HUS r Questions & Answers Mohammed Abdel Gawad Nephrology Specialist Kidney & Urology Center (KUC) Alexandria drgawad@gmail.com ESNT Outreach Program, Sohag, December 4-7, 2014
  • 2. To download the lecture with full animations please contact me on drgawad@gmail.com
  • 3. Questions What is meant by Thrombotic Microangiopathy (TMA)? What are the causes of TMA? What is the mechanism of TMA in TTP-HUS? What is the diagnostic approach of TTP-HUS & TMA? What are the treatment protocols of TTP-HUS? 1
  • 4. Questions What is meant by Thrombotic Microangiopathy (TMA)? What are the causes of TMA? What is the mechanism of TMA in TTP-HUS? What is the diagnostic approach of TTP-HUS & TMA? What are the treatment protocols of TTP-HUS? 1
  • 5. What is meant by Thrombotic Microangiopathy (TMA)? Intraluminal platelet thrombosis Thrombocytopenia Microangiopathic hemolytic anemia Consumption of platelets Hemolysis, Anemia, ↑LDH & Bilirubin 1
  • 6. Questions What is meant by Thrombotic Microangiopathy (TMA)? What are the causes of TMA? What is the mechanism of TMA in TTP-HUS? What is the diagnostic approach of TTP-HUS & TMA? What are the treatment protocols of TTP-HUS? 2
  • 7. Questions What is meant by Thrombotic Microangiopathy (TMA)? What are the causes of TMA? What is the mechanism of TMA in TTP-HUS? What is the diagnostic approach of TTP-HUS & TMA? What are the treatment protocols of TTP-HUS? 2
  • 8. What are the causes of ?TMA HIV, TTP/HUS 2
  • 9. Questions What is meant by Thrombotic Microangiopathy (TMA)? What are the causes of TMA? What is the mechanism of TMA in TTP-HUS? What is the diagnostic approach of TTP-HUS & TMA? What are the treatment protocols of TTP-HUS? 2
  • 10. Questions What is meant by Thrombotic Microangiopathy (TMA)? What are the causes of TMA? What is the mechanism of TMA in TTP-HUS? What is the diagnostic approach of TTP-HUS & TMA? What are the treatment protocols of TTP-HUS? 2
  • 11. What is the mechanism of TMA in TTP-HUS? Intraluminal platelet thrombosis Thrombocytopenia Microangiopathic hemolytic anemia Consumption of platelets Hemolysis, Anemia, ↑LDH & Bilirubin 2
  • 12. What is the mechanism of TMA in TTP-HUS? Intraluminal platelet thrombosis Consumption of platelets Thrombocytopenia TTP Shiga toxin HUS Neuraminidase HUS Atypical HUS 3
  • 13. What is the mechanism of TMA in TTP-HUS? Intraluminal platelet thrombosis Consumption of platelets Thrombocytopenia TTP Shiga toxin HUS Neuraminidase HUS Atypical HUS 3
  • 14. What is vWF role in ?body Flora Peyvandi et al. Blood Transfus 2011; 9 Suppl 2:s3-s8- . Romijn RAP et al. J Biol Chem 2001; 276: 9985-91- ·Leo T. Kroonen et al. Orthopedics. March 2008 - Volume 31- 3
  • 15. What is vWF role in ?body vWF activation = Platelets Aggregation & Adhesion Flora Peyvandi et al. Blood Transfus 2011; 9 Suppl 2:s3-s8- . Romijn RAP et al. J Biol Chem 2001; 276: 9985-91- ·Leo T. Kroonen et al. Orthopedics. March 2008 - Volume 31- 3
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23. TTP - Classification - H-M Tsai. Kidney International (2006) 70, 16–23. -Tsai HM. Annu Rev Med 2006; 57: 419–436. - Allford SL et al. Br J Haematol. 2003;120:556-573. 5
  • 24. What is the mechanism of TMA in TTP-HUS? Intraluminal platelet thrombosis Consumption of platelets Thrombocytopenia TTP Shiga toxin HUS ADAMTS 13 Neuraminidase HUS Atypical HUS 6
  • 25. What is the mechanism of TMA in TTP-HUS? Intraluminal platelet thrombosis Consumption of platelets Thrombocytopenia TTP Shiga toxin HUS ADAMTS 13 Neuraminidase HUS Atypical HUS 6
  • 26. Shiga Toxin Associated HUS E. coli (STEC) S. dysenteriae watery or most often bloody diarrhea E.Coli: Mostly the serotype O157:H7, but also other serotypes, such as O111:H8, O103:H2, O123, O26, O145, and the O104:H4 strain of the recent German outbreak Mead PS, Griffin PM. Lancet.1998;352:1207-1212. Ruggenenti P, Remuzzi G.Lancet. 2011;378:1057-1058. 6
  • 27. Shiga Toxin Associated HUS E. coli (STEC) S. dysenteriae watery or most often bloody diarrhea Mead PS, Griffin PM. Lancet.1998;352:1207-1212. Ruggenenti P, Remuzzi G.Lancet. 2011;378:1057-1058. 6
  • 28. Shiga Toxin Associated HUS E. coli (STEC) S. dysenteriae watery or most often bloody diarrhea Morigi M et al. Blood. 2001;98:1828-1835. Morigi M et al. J Immunol. 2011;187:172-180. 7
  • 29. Shiga Toxin Associated HUS E. coli (STEC) S. dysenteriae watery or most often bloody diarrhea Complement activation by alternative pathway: High plasma levels of complement activation products Bb and C5b-9 were measured in children with STEC-HUS Morigi M et al. Blood. 2001;98:1828-1835. Morigi M et al. J Immunol. 2011;187:172-180. 7
  • 30. What is the mechanism of Intraluminal platelet thrombosis Consumption of platelets Thrombocytopenia TTP Shiga toxin HUS ADAMTS 13 Neuraminidase HUS Atypical HUS Toxin binds endothelium TMA in TTP-HUS? 8
  • 31. What is the mechanism of Intraluminal platelet thrombosis Consumption of platelets Thrombocytopenia TTP Shiga toxin HUS ADAMTS 13 Neuraminidase HUS Atypical HUS Toxin binds endothelium TMA in TTP-HUS? 8
  • 32. Neuraminidase Associated HUS In infants and children. Complicate pneumonia, or less frequently, meningitis caused by S. pneumoniae erythrocytes, platelets, glomerular cells Brandt J, Wong C, Mihm S, et al. Pediatrics. 2002;110:371-376. Thomsen-Friedenreich antigen 8
  • 33. Neuraminidase Associated HUS In infants and children. Complicate pneumonia, or less frequently, meningitis caused by S. pneumoniae erythrocytes, platelets, glomerular cells Thomsen-Friedenreich antigen Polyagglutination Brandt J, Wong C, Mihm S, et al. Pediatrics. 2002;110:371-376. 8
  • 34. Neuraminidase Associated HUS In infants and children. Complicate pneumonia, or less frequently, meningitis caused by S. pneumoniae erythrocytes, platelets, glomerular cells Thomsen-Friedenreich antigen Polyagglutination Brandt J, Wong C, Mihm S, et al. Pediatrics. 2002;110:371-376. 8 Coomb’s +ve
  • 35. What is the mechanism of Intraluminal platelet thrombosis Consumption of platelets Thrombocytopenia TTP Shiga toxin HUS ADAMTS 13 Neuraminidase HUS Atypical HUS Toxin binds endothelium TMA in TTP-HUS? 8
  • 36. What is the mechanism of Intraluminal platelet thrombosis Consumption of platelets Thrombocytopenia TTP Shiga toxin HUS ADAMTS 13 Neuraminidase HUS Atypical HUS Toxin binds endothelium TMA in TTP-HUS? 8
  • 37. Atypical HUS Low serum C3 levels in aHUS with normal C4 indicate selective .alternative pathway activation Noris M, Ruggenenti P, Perna A, et al. J Am Soc Nephrol. 1999;10:281-293. 9
  • 38. Atypical HUS Caprioli J et al. Blood. 2006;108:1267-1279. Manuelian T, et al. J Clin Invest. 2003;111:1181-1190. 9
  • 41. Atypical HUS Acquired defects of CFH function are also seen in the form of inhibitory antibodies, reported in 5% to 10% of aHUS patients. Dragon-Durey MA, Loirat C, Cloarec S, et al. J Am Soc Nephrol. 2005;16:555-563. 10
  • 43. What is the mechanism of Intraluminal platelet thrombosis Consumption of platelets Thrombocytopenia TTP Shiga toxin HUS ADAMTS 13 Neuraminidase HUS Atypical HUS Toxin binds endothelium Alternative Complement TMA in TTP-HUS? 10
  • 44. What is the mechanism of TMA in TTP-HUS? Intraluminal platelet thrombosis Thrombocytopenia Microangiopathic hemolytic anemia Consumption of platelets Hemolysis, Anemia, ↑LDH & Bilirubin 11
  • 46. To download the lecture with full animations please contact me on drgawad@gmail.com
  • 47. Questions What is meant by Thrombotic Microangiopathy (TMA)? What are the causes of TMA? What is the mechanism of TMA in TTP-HUS? What is the diagnostic approach of TTP-HUS & TMA? What are the treatment protocols of TTP-HUS? 12
  • 48. Questions What is meant by Thrombotic Microangiopathy (TMA)? What are the causes of TMA? What is the mechanism of TMA in TTP-HUS? What is the diagnostic approach of TTP-HUS & TMA? What are the treatment protocols of TTP-HUS? 12
  • 49. Marie Scully et al. British Journal of Haematology, 2012, 158, 323– 335. HIV, DD of thrombocytopenia & MAHA Systematic Approach of Diagnosis 12
  • 50. Systematic Approach Marie Scully et al. British Journal of Haematology, 2012, 158, 323– 335. of Diagnosis Step 1 – Exclude Drugs 12
  • 51. Systematic Approach Piero Ruggenenti, Comprehensive Clinical Nephrology. 4th edition, chapter 28, p353 of Diagnosis Step 1 – Exclude Drugs 12
  • 52. Systematic Approach of Diagnosis Step 1 – Exclude Drugs Step 1 – Exclude Drugs 12
  • 53. Systematic Approach of Diagnosis - Marie Scully et al. British Journal of Haematology, 2012, 158, 323–335. - Patton JF et al. Am J Hematol. 1994;47:94-99. Step 2 – Autoimmune Hemolysis 13
  • 54. Systematic Approach of Diagnosis - Marie Scully et al. British Journal of Haematology, 2012, 158, 323–335. - Patton JF et al. Am J Hematol. 1994;47:94-99. Step 2 – Autoimmune Hemolysis 13
  • 55. Systematic Approach of Diagnosis - Marie Scully et al. British Journal of Haematology, 2012, 158, 323–335. - Patton JF et al. Am J Hematol. 1994;47:94-99. Step 2 – Autoimmune Hemolysis Step 3 13
  • 56. Systematic Approach of Diagnosis Step 3 – Coagulation Profile Step 4 – Exclude other causes 14
  • 57. Systematic Approach of Diagnosis Step 4 – Exclude other causes DD Suggestive Criteria Malignant Hypertension • Patient will have severe HTN: for example, systolic BP >200 mmHg, diastolic BP >130 mmHg. • It is extremely unlikely that a patient with TTP will present with severe HTN. • Microangiopathic haemolysis in patients with malignant HTN clears and thrombocytopenia resolves with BP management. Pre-eclampsia • New BP elevation and proteinuria after 20 weeks of gestation in a pregnant woman. • Although pregnancy is a risk factor for TTP and proteinuria can be present, patients with TTP do not generally have raised BP. 15
  • 58. Systematic Approach of Diagnosis Step 4 – Exclude other causes DD Suggestive Criteria Sepsis • Sepsis patients have hypotension • More pronounced fever • Raised white count with left shift. • Peripheral smear: vacuoles in the cytoplasm of neutrophils (highly specific for bacteraemia) • Blood cultures might be positive. Pregnancy Must be excluded. Autoimmune Disease ANA, RF, antiDNA, ACLA, lupus anticoagulant 16
  • 59. Systematic Approach of Diagnosis Step 4 – Exclude other causes HIV, 17
  • 60. Systematic Approach of Diagnosis Step 4 – Exclude other causes 17
  • 61. Systematic Approach of Diagnosis Step 4 – Exclude other causes • TTP has been reported in association with acute pancreatitis. • Sometimes a number of days after resolution of pancreatitis. • All patients were successfully treated with PEX and corticosteroids (McDonald et al, 2009). An association between thrombocytopenia and thyrotoxicosis has been reported 17
  • 62. Systematic Approach of Diagnosis Atypical HUS TTP Step 5 – TTP vs HUS Shiga toxin- HUS Neuraminidase -HUS 18
  • 63. Systematic Approach of Diagnosis Step 5 – TTP vs HUS Shiga toxin- HUS - Less than 2 years old - Respiratory distress, neurologic involvement, and coma. Neuraminidase -HUS - Occurs primarily in children, (except in epidemics with any age) -Watery or bloody diarrhoea. - Stool Culture: detection of E. coli O157:H7 and other STEC and their products in stool cultures (sorbitol-containing MacConkey agar - SMAC) Mead PS, Griffin PM. Lancet. 1998;352:1207-1212. 18
  • 64. Systematic Approach of Diagnosis Step 5 – TTP vs HUS Shiga toxin- HUS - Less than 2 years old - Respiratory distress, neurologic involvement, and coma. Neuraminidase -HUS - Occurs primarily in children, (except in epidemics with any age) -Watery or bloody diarrhoea. - Stool Culture: detection of E. coli O157:H7 and other STEC and their products in stool cultures (sorbitol-containing MacConkey agar - SMAC) Mead PS, Griffin PM. Lancet. 1998;352:1207-1212. 18
  • 65. Systematic Approach of Diagnosis Atypical HUS TTP Step 5 – TTP vs HUS Shiga toxin- HUS Neuraminidase -HUS 19
  • 66. Systematic Approach of Diagnosis Step 5 – TTP vs HUS Atypical HUS TTP Difficult to distinguish on clinical grounds only Moschcowitz E. Mt Sinai J Med. 2003;70:352-355. 19
  • 67. Systematic Approach of Diagnosis Step 5 – TTP vs HUS Atypical HUS TTP Difficult to distinguish on clinical grounds only TTP Pentad: 1. Microangiopathic haemolytic anaemia 2. Thrombocytopenia with purpura 3. Acute renal insufficiency 4. Neurological abnormalities 5. Fever is rare for all of these features (TTP pentad) to be seen. 19 -Vesely SK et al. Blood. 2003;102:60-68. -Marie Scully et al. British Journal of Haematology, 2012, 158, 323–335.
  • 68. Systematic Approach of Diagnosis Step 5 – TTP vs HUS Atypical HUS TTP Difficult to distinguish on clinical grounds only Differential diagnosis of aHUS is made on exclusion: • Of infections by STEC or neuraminidase - producing S.pneumoniae, • Of ADAMTS13 deficiency, • Of Systemic-associated diseases 20
  • 69. Systematic Approach of Diagnosis Step 5 – TTP vs HUS Atypical HUS TTP Difficult to distinguish on clinical grounds only Moschcowitz E. Mt Sinai J Med. 2003;70:352-355. Eknoyan G, Riggs SA. Am J Nephrol. 1986;6:117-131. 20
  • 70. Systematic Approach of Diagnosis Step 1: Exclusion of drugs Step 2: Exclusion of Autoimmune hemolysis Step 3: Coagulation Profile Step 4: Exclusion of other systemic causes Step 5: TTP vs HUS? 20
  • 71. Questions What is meant by Thrombotic Microangiopathy (TMA)? What are the causes of TMA? What is the mechanism of TMA in TTP-HUS? What is the diagnostic approach of TTP-HUS & TMA? What are the treatment protocols of TTP-HUS? 21
  • 72. Questions What is meant by Thrombotic Microangiopathy (TMA)? What are the causes of TMA? What is the mechanism of TMA in TTP-HUS? What is the diagnostic approach of TTP-HUS & TMA? What are the treatment protocols of TTP-HUS? 21
  • 73. Shiga Toxin Associated HUS E. coli (STEC) S. dysenteriae watery or most often bloody diarrhea Morigi M et al. Blood. 2001;98:1828-1835. Morigi M et al. J Immunol. 2011;187:172-180. 21
  • 74. Shiga Toxin Associated HUS Treatment Generally Supportive (including RRT if required) No role for anticoagulation No role for Antitimotility agents 21
  • 75. Shiga Toxin Associated HUS Treatment Generally Supportive (including RRT if required) No role for Antibiotics except: 1.Patients presenting with bacteremia 2.HUS, hemorrhagic colitis and HUS caused by Shigella dysentery type 1 3.Azithromycin had some benefit on the duration of bacterial shedding in adult patients from the German O104:H4 epidemic 21
  • 76. Shiga Toxin Associated HUS Treatment Generally Supportive (including RRT if required) Is there a role for plasma exchange? No prospective RCTs are available But comparative analyses of two large series of patients treated or not treated with plasma suggest that plasma therapy may dramatically decrease overall mortality of STEC O157:H7–associated HUS. Dundas S et al. Lancet. 1999;354:1327-1330. Carter AO et al. N Engl J Med. 1987;317:1496-1500. 22
  • 77. Atypical HUS Mutations or Antibodies Caprioli J et al. Blood. 2006;108:1267-1279. Manuelian T, et al. J Clin Invest. 2003;111:1181-1190. 22
  • 78. Atypical HUS Treatment Plasma exchange vs Plasma infusion Plasma Exchange is superior to Infusion: 1.Plasma exchange allows supplying larger amounts of plasma than would be possible with infusion while avoiding fluid overload. 2.Remission and prevention of recurrences, by removal of mutant CFH. 3.Plasma exchange is used to remove anti-CFH antibodies, but the effect is usually transient. Noris M, Remuzzi G. N Engl J Med. 2009;361:1676-1687. Dragon-Durey MA, et al. J Am Soc Nephrol. 2005;16:555-563. 23
  • 79. Atypical HUS Treatment Plasma exchange Immunosuppressants (corticosteroids and azathioprine or mycophenolate mofetil) combined with plasma exchange allowed long-term dialysis-free survival in 60% to 70% of patients. Dragon-Durey MA et al. J Am Soc Nephrol. 2010;21:2180-2187. 24
  • 80. Atypical HUS Treatment Licht C et al. J Am Soc Nephrol. 2011;22:197A. Greenbaum LA et al. J Am Soc Nephrol. 2011;22:197A. 24
  • 81. HUS Treatment 24 STEC - HUS Atypical HUS • General supportive • No anticoagulation • No antimotility drugs • No antibiotics (except some situations) • ??? PEX • Plasma Therapy (PEX is better) + Immunosuppressives • Eculizmab
  • 82. TTP - Classification - H-M Tsai. Kidney International (2006) 70, 16–23. -Tsai HM. Annu Rev Med 2006; 57: 419–436. - Allford SL et al. Br J Haematol. 2003;120:556-573. 25 ADAMTS13 activity < 5%, absence of Abs to ADAMTS13.
  • 83. Acquired TTP Treatment First Line Therapy 25
  • 84. Acquired TTP Treatment First Line Therapy 25
  • 85. What is the ideal time to start PEX sessions? 25 Acquired TTP Treatment First Line Therapy
  • 86. What is the ideal initial volume of exchange? X plasma 5·1 volume (PV) exchange on the first 3 d followed by 1·0 PV exchange thereafter Canadian ( apheresis trial )regimen 26 Acquired TTP Treatment First Line Therapy
  • 87. When to intensify PEX? 1. Refractory TTP (Progression of clinical symptoms or persistent thrombocytopenia despite seven daily PEX procedures) 2. New neurological insult 3. New cardiac insult 26 Acquired TTP Treatment First Line Therapy
  • 88. When to stop PEX? 27 Acquired TTP Treatment First Line Therapy
  • 89. When Plasma infusion is indicated? Although PEX remains the treatment of choice, large volume plasma infusions are indicated if there is to be a delay in arranging PEX. 27 Acquired TTP Treatment First Line Therapy Pereira A, Mazzara R, Monteagudo J, et al. Ann Hematol. 1995;70:319-323.
  • 90. First line within 4-6 hrs )volume exchange( Highly recommended ?? although no RCT If platelets > 50 Specially when hemolysis /Clinical situation Hemolysis Only if !!!! sever bleeding ?? If platelets > 50 ?When to intensify ?When to stop 28 Acquired TTP Treatment First Line Therapy
  • 91. Acquired TTP Treatment Other Options 29
  • 92. Acquired TTP Treatment Other Options 29 Refractory ??TTP Relapse ??TTP
  • 93. Refractory/ Relapsing TTP 29 Refractory TTP: Progression of clinical symptoms or persistent thrombocytopenia despite seven daily PEX procedures Relapsing TTP: Episode of acute TTP more than 30 d after remission, and occurs in 20–50% of cases.
  • 96. 30 Acquired TTP Treatment Other Options
  • 97. Refractory/ - Resistant Cases Initiation - (cardiac, )neurological Case Reports & small trials but recommended ?? Trials 30 Acquired TTP Treatment Other Options
  • 98. TTP - First described Dr. Eli Moschcowitz Arch Intern . Med. 1925;36:89 30
  • 99. To download the lecture with full animations please contact me on drgawad@gmail.com